Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on May 8, 2025

Precision Optics Schedules Third Quarter of Fiscal Year 2025 Conference Call for May 15, 2025
GARDNER, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that …

AMN Healthcare Announces First Quarter 2025 Results
Quarterly revenue of $690 million; GAAP loss of ($0.03)/share and adjusted EPS of $0.45 DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations …

Globus Medical Reports First Quarter 2025 Results
AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. Worldwide net sales were $598.1 million, a decrease …

CooperCompanies to Participate in the William Blair Growth Stock Conference
SAN RAMON, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today it will participate in the William Blair Growth Stock Conference on Thursday, June 5, 2025. Brian Andrews, Executive …

Progyny, Inc. Announces First Quarter 2025 Results
Reports Record Revenue of $324.0 Million, Reflecting 16.5% Growth Raises Full Year Guidance Due to Strong Start to the Year Early Selling Season Activity Reflects Ongoing Demand in Women's Health and Family Building Solutions NEW YORK, May 08, 2025 (GLOBE …

INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update
BOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces its financial results for the …

Oculis Reports Q1 2025 Financial Results and Provides Company Update
The recent R…

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates
– Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall 2025 – – New data from multiple programs highlighted …

Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15
DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system ( …

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
Six posters presented at the American Association for Cancer Research (AACR) annual meeting Appointment of Dr. Sabeen Mekan as Senior Vice President, Clinical Development Reported $321.6 million in cash resources as of March 31, 2025 (compared to $324.2 …

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non- …

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to date Initiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected in Q3 2025, with topline data from both 4FRONT-1 and …

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Regulatory Interactions and Commercial, Medical, and Corporate Preparations On-Track for Paltusotine New Drug Application with September 25, 2025 PDUFA Date CALM-CAH Phase 3 Study of Atumelnant for the Treatment of Adults with Congenital Adrenal …

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update
Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025 …

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025; Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025 Cash runway extending into the third quarter of 2026 with no debt Conference call …

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results
CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical …

Senseonics Holdings, Inc. Reports First Quarter Financial Results
Q1 Revenue of $6.3 million, growth year over year of 24% Partnership with Sequel integrates twiist™ automated insulin delivery (AID) system with Eversense® 365 one-year continuous glucose monitor (CGM); twiist with Eversense 365 launch expected in Q3 …

Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance
MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives …

Fulcrum Therapeutics to Participate in Upcoming May Conferences
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare …

Cytek Biosciences Reports First Quarter 2025 Financial Results
FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. First …